

**Experiment Number:** 20303 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride

**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012

**Time Report Requested:** 12:00:37

**First Dose M/F:** 06/20/05 / 06/20/05

**Lab:** BNW

F2\_M3

**NTP Study Number:** C20303  
**Lock Date:** 05/19/2008  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.6.0.0\_007  
**PWG Approval Date:** NONE

Experiment Number: 20303 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Vinylidene chloride  
 CAS Number: 75-35-4

Date Report Requested: 03/26/2012  
 Time Report Requested: 12:00:37  
 First Dose M/F: 06/20/05 / 06/20/05  
 Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
------------------	---------	----------	----------	--------

## Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	12	5	14	19
Natural Death	9	5	4	12
Survivors				
Moribund Sacrifice		1		
Natural Death				1
Terminal Sacrifice	29	39	32	18
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(42)	(45)	(47)	(41)
Intestine Large, Cecum	(47)	(48)	(48)	(40)
Artery, Inflammation				1 (3%)
Intestine Large, Colon	(47)	(48)	(48)	(42)
Intestine Large, Rectum	(48)	(48)	(48)	(42)
Intestine Small, Duodenum	(44)	(47)	(47)	(38)
Necrosis	1 (2%)		1 (2%)	
Intestine Small, Ileum	(44)	(47)	(47)	(39)
Hyperplasia			1 (2%)	
Intestine Small, Jejunum	(43)	(47)	(47)	(39)
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)		
Basophilic Focus	2 (4%)	4 (8%)	2 (4%)	7 (14%)
Clear Cell Focus	16 (32%)	11 (22%)	10 (20%)	8 (16%)
Cyst			2 (4%)	2 (4%)
Degeneration, Cystic			1 (2%)	1 (2%)
Eosinophilic Focus	9 (18%)	7 (14%)	4 (8%)	6 (12%)
Fatty Change	1 (2%)			
Infarct		1 (2%)		
Mineralization				1 (2%)
Mixed Cell Focus	2 (4%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Necrosis	5 (10%)	1 (2%)	2 (4%)	6 (12%)
Thrombosis		1 (2%)		
Mesentery	(6)	(9)	(6)	(3)
Fat, Necrosis	6 (100%)	8 (89%)	6 (100%)	1 (33%)
Pancreas	(50)	(49)	(50)	(48)
Artery, Inflammation, Chronic Active			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(49)	(50)	(50)	(49)
Hyperplasia, Squamous	4 (8%)	1 (2%)	7 (14%)	10 (20%)
Inflammation, Chronic Active	2 (4%)	2 (4%)	3 (6%)	7 (14%)
Mineralization		1 (2%)		
Necrosis	1 (2%)	2 (4%)	2 (4%)	4 (8%)
Ulcer	1 (2%)	1 (2%)		2 (4%)
Artery, Inflammation, Chronic Active				1 (2%)
Submucosa, Necrosis			1 (2%)	
Stomach, Glandular	(48)	(49)	(49)	(48)
Inflammation, Acute		1 (2%)		
Mineralization	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Necrosis	4 (8%)	3 (6%)	3 (6%)	5 (10%)
Tongue	(0)	(0)	(1)	(0)
Angiectasis			1 (100%)	
Tooth	(2)	(2)	(0)	(1)
Dysplasia	2 (100%)	2 (100%)		1 (100%)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(0)	(1)	(3)
Thrombosis				1 (33%)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	11 (22%)	10 (20%)	12 (24%)	13 (26%)
Thrombosis			2 (4%)	1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	2 (4%)
Endothelium, Hyperplasia				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

---

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hyperplasia	5 (10%)	6 (12%)	5 (10%)	3 (6%)
Hypertrophy	18 (36%)	11 (22%)	12 (24%)	10 (20%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia		3 (6%)	2 (4%)	3 (6%)
Islets, Pancreatic	(50)	(49)	(49)	(49)
Hyperplasia	3 (6%)	4 (8%)	4 (8%)	2 (4%)
Parathyroid Gland	(26)	(22)	(26)	(24)
Cyst			2 (8%)	1 (4%)
Pituitary Gland	(49)	(49)	(50)	(46)
Pars Distalis, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Thyroid Gland	(50)	(49)	(50)	(49)
Follicular Cell, Hyperplasia			1 (2%)	
<hr/>				
<b>GENERAL BODY SYSTEM</b>				
None				
<hr/>				
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm		1 (2%)	1 (2%)	
Inflammation, Chronic	1 (2%)		1 (2%)	
Spermatocele	1 (2%)			
Preputial Gland	(50)	(50)	(50)	(50)
Ectasia	1 (2%)	1 (2%)		
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic Active	3 (6%)	5 (10%)	3 (6%)	2 (4%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, Suppurative	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic Active			2 (4%)	1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Vinylidene chloride  
 CAS Number: 75-35-4

Date Report Requested: 03/26/2012  
 Time Report Requested: 12:00:37  
 First Dose M/F: 06/20/05 / 06/20/05  
 Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Seminal Vesicle	(50)	(50)	(50)	(50)
Dilatation				1 (2%)
Inflammation, Suppurative		1 (2%)		1 (2%)
Testes	(50)	(50)	(50)	(50)
Atrophy		2 (4%)		
Germinal Epithelium, Degeneration	2 (4%)	5 (10%)	3 (6%)	1 (2%)
Interstitial Cell, Hyperplasia		1 (2%)		2 (4%)

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(50)	(50)	(50)
Erythroid Cell, Depletion Cellular			1 (2%)	
Lymph Node	(2)	(2)	(0)	(2)
Lumbar, Hyperplasia, Lymphoid				1 (50%)
Lymph Node, Bronchial	(33)	(34)	(31)	(19)
Lymph Node, Mandibular	(17)	(29)	(19)	(25)
Hyperplasia	1 (6%)			
Lymph Node, Mediastinal	(43)	(29)	(43)	(38)
Lymph Node, Mesenteric	(46)	(48)	(48)	(47)
Angiectasis				2 (4%)
Inflammation, Granulomatous				2 (4%)
Necrosis		1 (2%)		
Artery, Inflammation, Chronic Active				1 (2%)
Spleen	(50)	(49)	(50)	(50)
Hematopoietic Cell Proliferation	1 (2%)	4 (8%)	2 (4%)	5 (10%)
Hyperplasia, Lymphoid	1 (2%)			
Lymphoid Follicle, Hyperplasia				1 (2%)
Thymus	(39)	(37)	(38)	(26)
Cyst	1 (3%)			
Necrosis	1 (3%)			

**INTEGUMENTARY SYSTEM**

Mammary Gland	(1)	(2)	(0)	(1)
Skin	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20303 - 06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride  
**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012  
**Time Report Requested:** 12:00:37  
**First Dose M/F:** 06/20/05 / 06/20/05  
**Lab:** BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Inflammation, Chronic Active	1 (2%)			
Necrosis	4 (8%)	5 (10%)	3 (6%)	3 (6%)
Epidermis, Hyperplasia, Squamous			1 (2%)	1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy				1 (2%)
Hyperostosis	1 (2%)			
Cartilage, Degeneration		1 (2%)		
Skeletal Muscle	(1)	(1)	(2)	(2)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Artery, Inflammation, Chronic Active				1 (2%)
<b>RESPIRATORY SYSTEM</b>				
Larynx	(50)	(50)	(50)	(49)
Foreign Body	1 (2%)			2 (4%)
Inflammation				1 (2%)
Inflammation, Suppurative	1 (2%)	1 (2%)		2 (4%)
Inflammation, Chronic Active	1 (2%)		1 (2%)	
Metaplasia, Squamous	1 (2%)			1 (2%)
Artery, Inflammation, Chronic Active				1 (2%)
Squamous Epithelium, Necrosis		1 (2%)		1 (2%)
Lung	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)		1 (2%)	
Inflammation, Chronic Active	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Thrombosis		1 (2%)		
Alveolar Epithelium, Hyperplasia	3 (6%)	7 (14%)	4 (8%)	6 (12%)
Alveolus, Infiltration Cellular, Histiocyte	4 (8%)		3 (6%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Serosa, Hyperplasia				1 (2%)
Nose	(50)	(50)	(49)	(49)
Foreign Body	2 (4%)		2 (4%)	4 (8%)
Hemorrhage			1 (2%)	
Hyperostosis	1 (2%)	27 (54%)	45 (92%)	48 (98%)
Inflammation, Suppurative	3 (6%)	2 (4%)	4 (8%)	7 (14%)
Inflammation, Chronic Active		1 (2%)		
Polyp, Inflammatory				1 (2%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	2 (4%)	5 (10%)	13 (27%)	11 (22%)
Olfactory Epithelium, Atrophy	1 (2%)	2 (4%)	1 (2%)	
Olfactory Epithelium, Metaplasia, Respiratory	17 (34%)	39 (78%)	47 (96%)	48 (98%)
Olfactory Epithelium, Necrosis	4 (8%)	1 (2%)	2 (4%)	4 (8%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	17 (34%)	21 (42%)	24 (49%)	16 (33%)
Respiratory Epithelium, Hyperplasia	37 (74%)	36 (72%)	35 (71%)	39 (80%)
Respiratory Epithelium, Metaplasia, Squamous	2 (4%)		3 (6%)	
Respiratory Epithelium, Necrosis	2 (4%)		2 (4%)	3 (6%)
Turbinates, Atrophy		46 (92%)	46 (94%)	47 (96%)
Turbinates, Necrosis			1 (2%)	
Pleura	(1)	(1)	(0)	(0)
Trachea	(50)	(50)	(50)	(50)
Inflammation, Suppurative	1 (2%)			1 (2%)
Inflammation, Chronic Active				1 (2%)
Epithelium, Necrosis				1 (2%)

## SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(48)
Cataract				1 (2%)
Degeneration			1 (2%)	
Necrosis				1 (2%)
Cornea, Hyperplasia, Squamous		1 (2%)		
Cornea, Inflammation, Chronic Active		1 (2%)	1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia		2 (4%)	3 (6%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20303 - 06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Vinylidene chloride  
**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012  
**Time Report Requested:** 12:00:37  
**First Dose M/F:** 06/20/05 / 06/20/05  
**Lab:** BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic Active		2 (4%)		
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Cyst	1 (2%)	1 (2%)	5 (10%)	7 (14%)
Hydronephrosis	2 (4%)		1 (2%)	3 (6%)
Infarct	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Inflammation, Chronic Active			1 (2%)	
Metaplasia, Osseous	2 (4%)	1 (2%)	1 (2%)	
Mineralization	1 (2%)			
Nephropathy	44 (88%)	46 (92%)	37 (74%)	44 (88%)
Papilla, Necrosis	1 (2%)			
Pelvis, Inflammation, Chronic Active			1 (2%)	
Renal Tubule, Hyperplasia		8 (16%)	22 (44%)	16 (32%)
Renal Tubule, Pigmentation		1 (2%)		
Transitional Epithelium, Hyperplasia			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(49)
Inflammation, Chronic Active		1 (2%)	1 (2%)	
Necrosis		1 (2%)		1 (2%)
Transitional Epithelium, Hyperplasia		2 (4%)	3 (6%)	1 (2%)

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20303 - 06  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride  
 CAS Number: 75-35-4

Date Report Requested: 03/26/2012  
 Time Report Requested: 12:00:37  
 First Dose M/F: 06/20/05 / 06/20/05  
 Lab: BNW

---

<b>B6C3F1 MICE FEMALE</b>	<b>Control</b>	<b>6.25 ppm</b>	<b>12.5 ppm</b>	<b>25 ppm</b>
---------------------------	----------------	-----------------	-----------------	---------------

---

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>
<b>Early Deaths</b>				
<b>Moribund Sacrifice</b>	<b>11</b>	<b>20</b>	<b>14</b>	<b>17</b>
<b>Natural Death</b>	<b>3</b>	<b>5</b>	<b>6</b>	<b>9</b>
<b>Survivors</b>				
<b>Moribund Sacrifice</b>				<b>1</b>
<b>Terminal Sacrifice</b>	<b>36</b>	<b>25</b>	<b>30</b>	<b>23</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

---

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(43)	(45)	(43)
Degeneration, Hyaline	1 (2%)			
Hyperplasia	1 (2%)			
Intestine Large, Cecum	(49)	(48)	(45)	(45)
Infiltration Cellular, Mast Cell			1 (2%)	
Inflammation, Chronic Active			1 (2%)	
Necrosis			2 (4%)	
Intestine Large, Colon	(49)	(47)	(46)	(46)
Intestine Large, Rectum	(49)	(47)	(47)	(46)
Intestine Small, Duodenum	(49)	(47)	(45)	(46)
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic Active			1 (2%)	
Intestine Small, Ileum	(49)	(48)	(45)	(45)
Hemorrhage			1 (2%)	
Hyperplasia		1 (2%)	2 (4%)	
Inflammation, Chronic Active			1 (2%)	
Ulcer	1 (2%)			
Intestine Small, Jejunum	(48)	(47)	(45)	(45)
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)		2 (4%)
Basophilic Focus	1 (2%)	4 (8%)		3 (6%)
Clear Cell Focus	5 (10%)	2 (4%)	6 (12%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Cyst			1 (2%)	
Eosinophilic Focus	9 (18%)	10 (20%)	9 (18%)	4 (8%)
Fatty Change	2 (4%)		2 (4%)	
Hemorrhage	1 (2%)			
Infarct	1 (2%)		1 (2%)	
Inflammation, Suppurative	1 (2%)	1 (2%)		
Inflammation, Chronic Active			2 (4%)	
Mixed Cell Focus				1 (2%)
Necrosis	2 (4%)	3 (6%)	6 (12%)	3 (6%)
Vacuolization Cytoplasmic				1 (2%)
Mesentery	(10)	(16)	(19)	(37)
Angiectasis			1 (5%)	
Infiltration Cellular, Mononuclear Cell				1 (3%)
Artery, Inflammation	1 (10%)			
Fat, Necrosis	8 (80%)	14 (88%)	15 (79%)	33 (89%)
Pancreas	(50)	(49)	(50)	(50)
Atrophy				1 (2%)
Cyst		1 (2%)	1 (2%)	
Fibrosis		1 (2%)		
Inflammation, Chronic Active	1 (2%)	1 (2%)		
Necrosis	1 (2%)			1 (2%)
Artery, Inflammation, Chronic Active	2 (4%)			
Salivary Glands	(50)	(50)	(50)	(50)
Inflammation, Suppurative			1 (2%)	
Necrosis		1 (2%)		
Stomach, Forestomach	(50)	(49)	(50)	(50)
Hyperplasia, Squamous	2 (4%)	2 (4%)		2 (4%)
Inflammation, Chronic Active				1 (2%)
Necrosis		1 (2%)	1 (2%)	4 (8%)
Ulcer	1 (2%)			1 (2%)
Artery, Inflammation, Chronic Active		1 (2%)		
Stomach, Glandular	(49)	(48)	(49)	(49)
Mineralization	2 (4%)	2 (4%)	2 (4%)	
Necrosis		1 (2%)	3 (6%)	1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Tooth	(0)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Dysplasia		1 (100%)		
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(0)	(1)	(0)	(0)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	9 (18%)	12 (24%)	12 (24%)	9 (18%)
Inflammation, Suppurative			1 (2%)	
Mineralization	2 (4%)	1 (2%)		
Necrosis, Chronic		1 (2%)		
Thrombosis		2 (4%)	1 (2%)	3 (6%)
Artery, Inflammation, Chronic Active	2 (4%)	2 (4%)		
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(49)	(50)	(49)
Angiectasis	1 (2%)	1 (2%)		
Hyperplasia	6 (12%)	6 (12%)	8 (16%)	8 (16%)
Hypertrophy	4 (8%)		5 (10%)	3 (6%)
Inflammation, Suppurative		1 (2%)		
Vacuolization Cytoplasmic			1 (2%)	
Subcapsular, Hyperplasia		1 (2%)		
Adrenal Medulla	(50)	(48)	(50)	(49)
Hyperplasia	1 (2%)	3 (6%)	1 (2%)	4 (8%)
Inflammation, Suppurative		1 (2%)		
Islets, Pancreatic	(50)	(49)	(50)	(50)
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	3 (6%)
Parathyroid Gland	(24)	(22)	(21)	(31)
Pituitary Gland	(50)	(50)	(48)	(47)
Pars Distalis, Angiectasis			2 (4%)	1 (2%)
Pars Distalis, Cyst				1 (2%)
Pars Distalis, Hyperplasia	6 (12%)	9 (18%)	8 (17%)	8 (17%)
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Hyperplasia		2 (4%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20303 - 06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride  
**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012  
**Time Report Requested:** 12:00:37  
**First Dose M/F:** 06/20/05 / 06/20/05  
**Lab:** BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(45)	(46)	(45)	(45)
Hyperplasia			1 (2%)	
Inflammation, Chronic Active				1 (2%)
Ovary	(50)	(49)	(49)	(49)
Angiectasis			2 (4%)	
Cyst	6 (12%)	6 (12%)	12 (24%)	2 (4%)
Thrombosis		2 (4%)	2 (4%)	1 (2%)
Uterus	(50)	(49)	(50)	(50)
Adenomyosis			1 (2%)	
Angiectasis			1 (2%)	
Hemorrhage			1 (2%)	
Inflammation, Suppurative		1 (2%)	1 (2%)	
Inflammation, Histiocytic, Chronic Active	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Necrosis			1 (2%)	
Thrombosis	1 (2%)		2 (4%)	1 (2%)
Ulcer		1 (2%)		
Endometrium, Hyperplasia, Cystic	36 (72%)	41 (84%)	46 (92%)	46 (92%)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(49)	(50)	(50)
Thrombosis				1 (2%)
Myeloid Cell, Hyperplasia		1 (2%)	2 (4%)	1 (2%)
Lymph Node	(8)	(11)	(1)	(8)
Hyperplasia, Lymphoid				1 (13%)
Iliac, Ectasia		1 (9%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Lumbar, Renal, Angiectasis	1 (13%)			
Lumbar, Renal, Inflammation, Granulomatous	1 (13%)			
Renal, Angiectasis	1 (13%)			
Renal, Ectasia				1 (13%)
Lymph Node, Bronchial	(25)	(38)	(38)	(38)
Lymph Node, Mandibular	(31)	(35)	(30)	(37)
Angiectasis		1 (3%)		1 (3%)
Lymph Node, Mediastinal	(42)	(45)	(45)	(47)
Lymph Node, Mesenteric	(47)	(48)	(47)	(45)
Hemorrhage				1 (2%)
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	
Spleen	(50)	(49)	(50)	(49)
Hematopoietic Cell Proliferation	3 (6%)	6 (12%)	7 (14%)	9 (18%)
Necrosis		1 (2%)		
Thymus	(47)	(44)	(46)	(40)
Cyst				1 (3%)

## INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		3 (6%)
Skin	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Inflammation, Chronic Active				1 (2%)
Necrosis	3 (6%)	2 (4%)	2 (4%)	

## MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Cyst				1 (2%)
Degeneration				1 (2%)
Hyperostosis		1 (2%)		
Skeletal Muscle	(3)	(3)	(2)	(4)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20303 - 06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride  
**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012  
**Time Report Requested:** 12:00:37  
**First Dose M/F:** 06/20/05 / 06/20/05  
**Lab:** BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Artery, Meninges, Inflammation, Chronic Active	1 (2%)			1 (2%)
Peripheral Nerve	(2)	(2)	(0)	(0)
Spinal Cord	(2)	(2)	(0)	(1)
<b>RESPIRATORY SYSTEM</b>				
Larynx	(50)	(50)	(49)	(49)
Degeneration, Hyaline	1 (2%)			
Inflammation, Suppurative		1 (2%)		
Metaplasia, Squamous	2 (4%)		1 (2%)	1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)			
Squamous Epithelium, Necrosis			1 (2%)	
Lung	(50)	(50)	(50)	(49)
Degeneration, Hyaline	1 (2%)			
Fibrosis				1 (2%)
Hemorrhage		1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic Active	2 (4%)	5 (10%)	3 (6%)	4 (8%)
Alveolar Epithelium, Hyperplasia	3 (6%)	1 (2%)	4 (8%)	3 (6%)
Alveolus, Infiltration Cellular, Histiocyte	3 (6%)	1 (2%)	3 (6%)	3 (6%)
Perivascular, Inflammation, Chronic Active				2 (4%)
Vein, Necrosis		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Foreign Body		1 (2%)	1 (2%)	2 (4%)
Hyperostosis		13 (26%)	45 (90%)	48 (96%)
Inflammation, Suppurative		1 (2%)	3 (6%)	5 (10%)
Inflammation, Chronic Active	2 (4%)	1 (2%)		2 (4%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	18 (36%)	18 (36%)	13 (26%)	32 (64%)
Olfactory Epithelium, Metaplasia, Respiratory	3 (6%)	29 (58%)	49 (98%)	50 (100%)
Olfactory Epithelium, Necrosis			2 (4%)	1 (2%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	38 (76%)	33 (66%)	29 (58%)	42 (84%)
Respiratory Epithelium, Hyperplasia	33 (66%)	41 (82%)	39 (78%)	43 (86%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20303 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Vinylidene chloride

CAS Number: 75-35-4

Date Report Requested: 03/26/2012

Time Report Requested: 12:00:37

First Dose M/F: 06/20/05 / 06/20/05

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Respiratory Epithelium, Metaplasia, Squamous	3 (6%)	2 (4%)	3 (6%)	7 (14%)
Respiratory Epithelium, Necrosis	1 (2%)	3 (6%)	5 (10%)	4 (8%)
Turbinate, Atrophy		46 (92%)	50 (100%)	49 (98%)
Trachea	(50)	(50)	(50)	(49)
Degeneration, Hyaline	1 (2%)			
Foreign Body	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Artery, Inflammation, Chronic Active		1 (2%)		

## SPECIAL SENSES SYSTEM

Eye	(50)	(49)	(50)	(49)
Cataract		1 (2%)	1 (2%)	
Degeneration			1 (2%)	
Cornea, Inflammation, Suppurative				1 (2%)
Cornea, Necrosis				1 (2%)
Harderian Gland	(50)	(50)	(50)	(48)
Hyperplasia	1 (2%)	1 (2%)	2 (4%)	2 (4%)

## URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Cyst		2 (4%)	1 (2%)	
Hydronephrosis	2 (4%)		1 (2%)	3 (6%)
Infarct	5 (10%)	5 (10%)	2 (4%)	
Inflammation, Chronic Active		1 (2%)		
Metaplasia, Osseous	3 (6%)		2 (4%)	3 (6%)
Nephropathy	26 (52%)	28 (56%)	38 (76%)	35 (70%)
Artery, Inflammation, Chronic Active	2 (4%)	3 (6%)		1 (2%)
Glomerulus, Amyloid Deposition		1 (2%)		1 (2%)
Papilla, Inflammation, Suppurative			1 (2%)	
Renal Tubule, Necrosis		1 (2%)		
Renal Tubule, Pigmentation			1 (2%)	
Urinary Bladder	(49)	(49)	(48)	(48)
Artery, Inflammation, Chronic Active	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 20303 - 06  
**Test Type:** CHRONIC  
**Route:** RESPIRATORY EXPOSURE WHOLE BODY  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Vinylidene chloride  
**CAS Number:** 75-35-4

**Date Report Requested:** 03/26/2012  
**Time Report Requested:** 12:00:37  
**First Dose M/F:** 06/20/05 / 06/20/05  
**Lab:** BNW

---

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Transitional Epithelium, Hyperplasia	1 (2%)			

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion